Comparative study of bay o 9867 (ciprofloxacin) and bacampicillin on bacterial pneumonia by double blind method

Kohei Hara; Atsushi Saito; Keizo Yamaguchi; Yoji Suzuyama; Yoshiteru Shigeno; Shigeru Kohno; Koichi Watanabe; Kin Ichi Izumikawa; Tsunetoshi Koteda; Kazuhiro Okuno; Takashige Miyazaki; Tsuneo Tsutsumi; Masumi Tomizawa; Ichiro Nakayama; Yohmei Hiraga; Kohki Kikuchi; Asako Yamamoto; Kazuo Takebe; Yoshihiro Kumasaka; Kazumi Aoyagi; Toyokazu Tamura; Keiichi Sekino; Tatsuro Irie; Morio Sagara; Katsuhiro Okamoto; Masao Tamura; Kazuki Konishi; Ataru Daibo; Hiroshi Kuramitsu; Kazutoshi Gomi; Kotaro Itakura; Nobuhisa Sato; Kazuo Tanifuji; Kiyoshi Konno; Kotaro Oizumi; Seiichi Aonuma; Kosaku Nagai; Izumi Hayashi; Masataka Katsu; Shinji Okui; Toshio Fukui; Minoru Sato; Takasht Yokosr; Takeo Toyota; Mieko Kawai; Hajime Yamagata; Teruo Aoyagi; Shigeo Yoshizawa; Tetsuji Katayama; Fuyuhiko Higashi; Gohta Masuda; Masayoshi Negishi; Chenden Young; Osamu Sekine; Yoshimaru Usuda; Nobuki Aoki; Fusanosuke Yamasaki; Yasutoshi Suzuki; Hiroyuki Kobayashi; Kenji Takamura; Hiroaki Takeda; Kota Kono; Masakazu Katoh; Yoshiji Yamane; Keimei Mashimo; Junzaburo Kabe; Hiroyoshi Ishibashi; Yasuyuki Sano; Koichiro Kudo; Yuko Uno; Hideo Ikemoto; Kazuyoshi Watanabe; Hiroichi Tanimoto; Koichiro Nakata; Yoshitaka Nakamori; Naohiko Chonabayashi; Ryuo Nakatani; Kunihiko Yoshimura; Tadashi Miyahara; Masaru Koyama; Kentaro Watanabe; Fukuo Iijima; Yoshio Kobayashi; Ippei Fujimori; Takehiko Tominaga; Takao Okubo; Akira Ito; Makio Kurihara; Kaitaro Yamabe; Kazufuto Fukaya; Fumio Matsumoto; Shigeki Odagiri; Masanori Matsumura; Kaneo Suzuki; Koou Murohashi; Hisako Suzuki; Yasuhiro Yoshiike; Mitsuyo Kiuchi; Tsutomu Fukuda; Kaoru Oyama; Toshihiko Takeuchi; Masahito Kato; Hidekazu Hanaki; Toshiyuki Yamamoto; Hideki Nishiyama; Takekuni Iwata; Kazukiyo Oida; Yoshiro Mochizuki; Mitsuo Hase; Yujiro Suzuki; Nobuaki Ikeda; Shozo Fujino; Tetsuya Matsumoto; Hiroyuki Tsujino; Kenji Bando; Naoaki Kuroda; Fumiyuki Kuze; Yuruko Okamoto; Seibun Yonezu; Yube Iida; Yoshihiko Sakakibara; KōZiro Yasunaga; Yoshihiro Ueda; Hiroshi Okubo; Fumio Miki; Yoshiyasu Ikuno; Eiji Inoue; Akihito Murata; Shin Ichi Tanizawa; Kazuo Sakamoto; Hirozumi Sakai; Rinzo Soejima; Hiroshi Kawane; Yoshihito Niki; Yoshihisa Nakagawa; Osamu Moriya; Eiro Tsubura; Masakazu Tamura; Toshihiro Gotoh; Masaru Nakagawa; Koichi Fukuyama; Tadaaki Morimoto; I. Teiho; Masami Ito; Naoyoshi Kojiro; Osamu Kurimura; Hideo Sasaki; Hirofumi Fukuhara; Tadao Morimoto; Yoshiro Sawae; Kaoru Okada; Yukio Kumagai; Hitoshi Nagano; Torao Inoue; Chiharu Kubo; Keizo Matsumoto; Harumi Shishido; Tomoyuki Harada; Masaru Nasu; Jun Goto; Yoichiro Goto; Takayoshi Tashiro; Takashi Itoga; Moritaka Suga; Masayuki Ando; Shukuro Araki; Kazumine Kobari; Masao Nakatomi; Yutoku Kinjo; Tatsuo Ohgimi; Katsuyoshi Shimoji; Yuei Irabu

doi:10.11250/chemotherapy1953.34.629

Comparative study of bay o 9867 (ciprofloxacin) and bacampicillin on bacterial pneumonia by double blind method

Kohei Hara, Atsushi Saito, Keizo Yamaguchi, Yoji Suzuyama, Yoshiteru Shigeno, Shigeru Kohno, Koichi Watanabe, Kin Ichi Izumikawa, Tsunetoshi Koteda, Kazuhiro Okuno, Takashige Miyazaki, Tsuneo Tsutsumi, Masumi Tomizawa, Ichiro Nakayama, Yohmei Hiraga, Kohki Kikuchi, Asako Yamamoto, Kazuo Takebe, Yoshihiro Kumasaka, Kazumi AoyagiToyokazu Tamura, Keiichi Sekino, Tatsuro Irie, Morio Sagara, Katsuhiro Okamoto, Masao Tamura, Kazuki Konishi, Ataru Daibo, Hiroshi Kuramitsu, Kazutoshi Gomi, Kotaro Itakura, Nobuhisa Sato, Kazuo Tanifuji, Kiyoshi Konno, Kotaro Oizumi, Seiichi Aonuma, Kosaku Nagai, Izumi Hayashi, Masataka Katsu, Shinji Okui, Toshio Fukui, Minoru Sato, Takasht Yokosr, Takeo Toyota, Mieko Kawai, Hajime Yamagata, Teruo Aoyagi, Shigeo Yoshizawa, Tetsuji Katayama, Fuyuhiko Higashi, Gohta Masuda, Masayoshi Negishi, Chenden Young, Osamu Sekine, Yoshimaru Usuda, Nobuki Aoki, Fusanosuke Yamasaki, Yasutoshi Suzuki, Hiroyuki Kobayashi, Kenji Takamura, Hiroaki Takeda, Kota Kono, Masakazu Katoh, Yoshiji Yamane, Keimei Mashimo, Junzaburo Kabe, Hiroyoshi Ishibashi, Yasuyuki Sano, Koichiro Kudo, Yuko Uno, Hideo Ikemoto, Kazuyoshi Watanabe, Hiroichi Tanimoto, Koichiro Nakata, Yoshitaka Nakamori, Naohiko Chonabayashi, Ryuo Nakatani, Kunihiko Yoshimura, Tadashi Miyahara, Masaru Koyama, Kentaro Watanabe, Fukuo Iijima, Yoshio Kobayashi, Ippei Fujimori, Takehiko Tominaga, Takao Okubo, Akira Ito, Makio Kurihara, Kaitaro Yamabe, Kazufuto Fukaya, Fumio Matsumoto, Shigeki Odagiri, Masanori Matsumura, Kaneo Suzuki, Koou Murohashi, Hisako Suzuki, Yasuhiro Yoshiike, Mitsuyo Kiuchi, Tsutomu Fukuda, Kaoru Oyama, Toshihiko Takeuchi, Masahito Kato, Hidekazu Hanaki, Toshiyuki Yamamoto, Hideki Nishiyama, Takekuni Iwata, Kazukiyo Oida, Yoshiro Mochizuki, Mitsuo Hase, Yujiro Suzuki, Nobuaki Ikeda, Shozo Fujino, Tetsuya Matsumoto, Hiroyuki Tsujino, Kenji Bando, Naoaki Kuroda, Fumiyuki Kuze, Yuruko Okamoto, Seibun Yonezu, Yube Iida, Yoshihiko Sakakibara, KōZiro Yasunaga, Yoshihiro Ueda, Hiroshi Okubo, Fumio Miki, Yoshiyasu Ikuno, Eiji Inoue, Akihito Murata, Shin Ichi Tanizawa, Kazuo Sakamoto, Hirozumi Sakai, Rinzo Soejima, Hiroshi Kawane, Yoshihito Niki, Yoshihisa Nakagawa, Osamu Moriya, Eiro Tsubura, Masakazu Tamura, Toshihiro Gotoh, Masaru Nakagawa, Koichi Fukuyama, Tadaaki Morimoto, I. Teiho, Masami Ito, Naoyoshi Kojiro, Osamu Kurimura, Hideo Sasaki, Hirofumi Fukuhara, Tadao Morimoto, Yoshiro Sawae, Kaoru Okada, Yukio Kumagai, Hitoshi Nagano, Torao Inoue, Chiharu Kubo, Keizo Matsumoto, Harumi Shishido, Tomoyuki Harada, Masaru Nasu, Jun Goto, Yoichiro Goto, Takayoshi Tashiro, Takashi Itoga, Moritaka Suga, Masayuki Ando, Shukuro Araki, Kazumine Kobari, Masao Nakatomi, Yutoku Kinjo, Tatsuo Ohgimi, Katsuyoshi Shimoji, Yuei Irabu

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

The clinical effectiveness and safety of BAY o 9867 (Ciprofloxacin, CPFX) in the treatment of the patients with bacterial pneumonia were compared with those of bacampicillin (BAPC) by a double-dummy fashion. Patients over 18 years old with apparent clinical signs and symptoms of pneumonia were administered with CPFX at a daily dose of 600 mg or BAPC at a daily dose of 1 g orally for 14 days in principle. The following results were obtained. 1) On the basis of committee judgement, the clinical efficacy rate in the total cases including non-bacterial pneumonia was 85.3% (58/68) in CPFX group and 90.5% (57/63) in BAPC group, respectively. In bacterial pneumonia, the rate was 83.3% (45/54) in CPFX group and 88. 9% (40/45) in BAPC group, respectively. The differences between the two groups in both analyses were statistically not significant. 2) The clinical efficacy rate by doctors in charge in the total cases was 87.7% (57/65) in CPFX group and 86.9% (53/61) in BAPC group, respectively. In bacterial pneumonia, the rate was 86.8% (46/53) for CPFX group and 87.2% (41/47) for BAPC group, respectively. In both analyses, the differences between the two groups were statistically not significant. 3) As for the bacteriological response, the eradication rate in the total cases was 85.7% (18/21) in CPFX group and 65. 0% (13/20) in BAPC group, respectively. In bacterial pneumonia, the eradication rate was 83.3% (15/18) in CPFX group and 56.3% (9/16) in BAPC group, respectively. In both analyses, the rates of CPFX were higher than those of BAPC, but statistically, the differences between the two groups were not significant. 4) Side effects were noted in 7 of 83 cases (8. 4%) treated with CPFX and 8 of 84 cases (9. 5%) with BAPC, and abnormal changes in laboratory findings were noted in 12 of 80 cases (15.0%) with CPFX and 18 of 77 cases (23.4%) with BAPC. The differences between the two groups were not significant statistically. Neither serious side effect nor remarkable abnormal change in laboratory findings was noted. 5) The utility rates judged by the committee members and by doctors in charge were not significantly different between the two groups. From these results, it is considered that the clinical efficacy and safety of CPFX at a daily dose of 600 mg are equal to those of BAPC at a daily dose of 1g in the treatment of the patients with bacterial pneumonia.

Original language	English
Pages (from-to)	629-653
Number of pages	25
Journal	Chemotherapy
Volume	34
Issue number	7
DOIs	https://doi.org/10.11250/chemotherapy1953.34.629
Publication status	Published - 1986
Externally published	Yes

All Science Journal Classification (ASJC) codes

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.34.629

Cite this

Hara, K., Saito, A., Yamaguchi, K., Suzuyama, Y., Shigeno, Y., Kohno, S., Watanabe, K., Izumikawa, K. I., Koteda, T., Okuno, K., Miyazaki, T., Tsutsumi, T., Tomizawa, M., Nakayama, I., Hiraga, Y., Kikuchi, K., Yamamoto, A., Takebe, K., Kumasaka, Y., ... Irabu, Y. (1986). Comparative study of bay o 9867 (ciprofloxacin) and bacampicillin on bacterial pneumonia by double blind method. Chemotherapy, 34(7), 629-653. https://doi.org/10.11250/chemotherapy1953.34.629

Hara, K, Saito, A, Yamaguchi, K, Suzuyama, Y, Shigeno, Y, Kohno, S, Watanabe, K, Izumikawa, KI, Koteda, T, Okuno, K, Miyazaki, T, Tsutsumi, T, Tomizawa, M, Nakayama, I, Hiraga, Y, Kikuchi, K, Yamamoto, A, Takebe, K, Kumasaka, Y, Aoyagi, K, Tamura, T, Sekino, K, Irie, T, Sagara, M, Okamoto, K, Tamura, M, Konishi, K, Daibo, A, Kuramitsu, H, Gomi, K, Itakura, K, Sato, N, Tanifuji, K, Konno, K, Oizumi, K, Aonuma, S, Nagai, K, Hayashi, I, Katsu, M, Okui, S, Fukui, T, Sato, M, Yokosr, T, Toyota, T, Kawai, M, Yamagata, H, Aoyagi, T, Yoshizawa, S, Katayama, T, Higashi, F, Masuda, G, Negishi, M, Young, C, Sekine, O, Usuda, Y, Aoki, N, Yamasaki, F, Suzuki, Y, Kobayashi, H, Takamura, K, Takeda, H, Kono, K, Katoh, M, Yamane, Y, Mashimo, K, Kabe, J, Ishibashi, H, Sano, Y, Kudo, K, Uno, Y, Ikemoto, H, Watanabe, K, Tanimoto, H, Nakata, K, Nakamori, Y, Chonabayashi, N, Nakatani, R, Yoshimura, K, Miyahara, T, Koyama, M, Watanabe, K, Iijima, F, Kobayashi, Y, Fujimori, I, Tominaga, T, Okubo, T, Ito, A, Kurihara, M, Yamabe, K, Fukaya, K, Matsumoto, F, Odagiri, S, Matsumura, M, Suzuki, K, Murohashi, K, Suzuki, H, Yoshiike, Y, Kiuchi, M, Fukuda, T, Oyama, K, Takeuchi, T, Kato, M, Hanaki, H, Yamamoto, T, Nishiyama, H, Iwata, T, Oida, K, Mochizuki, Y, Hase, M, Suzuki, Y, Ikeda, N, Fujino, S, Matsumoto, T, Tsujino, H, Bando, K, Kuroda, N, Kuze, F, Okamoto, Y, Yonezu, S, Iida, Y, Sakakibara, Y, Yasunaga, K, Ueda, Y, Okubo, H, Miki, F, Ikuno, Y, Inoue, E, Murata, A, Tanizawa, SI, Sakamoto, K, Sakai, H, Soejima, R, Kawane, H, Niki, Y, Nakagawa, Y, Moriya, O, Tsubura, E, Tamura, M, Gotoh, T, Nakagawa, M, Fukuyama, K, Morimoto, T, Teiho, I, Ito, M, Kojiro, N, Kurimura, O, Sasaki, H, Fukuhara, H, Morimoto, T, Sawae, Y, Okada, K, Kumagai, Y, Nagano, H, Inoue, T, Kubo, C, Matsumoto, K, Shishido, H, Harada, T, Nasu, M, Goto, J, Goto, Y, Tashiro, T, Itoga, T, Suga, M, Ando, M, Araki, S, Kobari, K, Nakatomi, M, Kinjo, Y, Ohgimi, T, Shimoji, K & Irabu, Y 1986, 'Comparative study of bay o 9867 (ciprofloxacin) and bacampicillin on bacterial pneumonia by double blind method', Chemotherapy, vol. 34, no. 7, pp. 629-653. https://doi.org/10.11250/chemotherapy1953.34.629

@article{92d8ab1860cd46259d177570b2f3e66e,

title = "Comparative study of bay o 9867 (ciprofloxacin) and bacampicillin on bacterial pneumonia by double blind method",

abstract = "The clinical effectiveness and safety of BAY o 9867 (Ciprofloxacin, CPFX) in the treatment of the patients with bacterial pneumonia were compared with those of bacampicillin (BAPC) by a double-dummy fashion. Patients over 18 years old with apparent clinical signs and symptoms of pneumonia were administered with CPFX at a daily dose of 600 mg or BAPC at a daily dose of 1 g orally for 14 days in principle. The following results were obtained. 1) On the basis of committee judgement, the clinical efficacy rate in the total cases including non-bacterial pneumonia was 85.3% (58/68) in CPFX group and 90.5% (57/63) in BAPC group, respectively. In bacterial pneumonia, the rate was 83.3% (45/54) in CPFX group and 88. 9% (40/45) in BAPC group, respectively. The differences between the two groups in both analyses were statistically not significant. 2) The clinical efficacy rate by doctors in charge in the total cases was 87.7% (57/65) in CPFX group and 86.9% (53/61) in BAPC group, respectively. In bacterial pneumonia, the rate was 86.8% (46/53) for CPFX group and 87.2% (41/47) for BAPC group, respectively. In both analyses, the differences between the two groups were statistically not significant. 3) As for the bacteriological response, the eradication rate in the total cases was 85.7% (18/21) in CPFX group and 65. 0% (13/20) in BAPC group, respectively. In bacterial pneumonia, the eradication rate was 83.3% (15/18) in CPFX group and 56.3% (9/16) in BAPC group, respectively. In both analyses, the rates of CPFX were higher than those of BAPC, but statistically, the differences between the two groups were not significant. 4) Side effects were noted in 7 of 83 cases (8. 4%) treated with CPFX and 8 of 84 cases (9. 5%) with BAPC, and abnormal changes in laboratory findings were noted in 12 of 80 cases (15.0%) with CPFX and 18 of 77 cases (23.4%) with BAPC. The differences between the two groups were not significant statistically. Neither serious side effect nor remarkable abnormal change in laboratory findings was noted. 5) The utility rates judged by the committee members and by doctors in charge were not significantly different between the two groups. From these results, it is considered that the clinical efficacy and safety of CPFX at a daily dose of 600 mg are equal to those of BAPC at a daily dose of 1g in the treatment of the patients with bacterial pneumonia.",

author = "Kohei Hara and Atsushi Saito and Keizo Yamaguchi and Yoji Suzuyama and Yoshiteru Shigeno and Shigeru Kohno and Koichi Watanabe and Izumikawa, {Kin Ichi} and Tsunetoshi Koteda and Kazuhiro Okuno and Takashige Miyazaki and Tsuneo Tsutsumi and Masumi Tomizawa and Ichiro Nakayama and Yohmei Hiraga and Kohki Kikuchi and Asako Yamamoto and Kazuo Takebe and Yoshihiro Kumasaka and Kazumi Aoyagi and Toyokazu Tamura and Keiichi Sekino and Tatsuro Irie and Morio Sagara and Katsuhiro Okamoto and Masao Tamura and Kazuki Konishi and Ataru Daibo and Hiroshi Kuramitsu and Kazutoshi Gomi and Kotaro Itakura and Nobuhisa Sato and Kazuo Tanifuji and Kiyoshi Konno and Kotaro Oizumi and Seiichi Aonuma and Kosaku Nagai and Izumi Hayashi and Masataka Katsu and Shinji Okui and Toshio Fukui and Minoru Sato and Takasht Yokosr and Takeo Toyota and Mieko Kawai and Hajime Yamagata and Teruo Aoyagi and Shigeo Yoshizawa and Tetsuji Katayama and Fuyuhiko Higashi and Gohta Masuda and Masayoshi Negishi and Chenden Young and Osamu Sekine and Yoshimaru Usuda and Nobuki Aoki and Fusanosuke Yamasaki and Yasutoshi Suzuki and Hiroyuki Kobayashi and Kenji Takamura and Hiroaki Takeda and Kota Kono and Masakazu Katoh and Yoshiji Yamane and Keimei Mashimo and Junzaburo Kabe and Hiroyoshi Ishibashi and Yasuyuki Sano and Koichiro Kudo and Yuko Uno and Hideo Ikemoto and Kazuyoshi Watanabe and Hiroichi Tanimoto and Koichiro Nakata and Yoshitaka Nakamori and Naohiko Chonabayashi and Ryuo Nakatani and Kunihiko Yoshimura and Tadashi Miyahara and Masaru Koyama and Kentaro Watanabe and Fukuo Iijima and Yoshio Kobayashi and Ippei Fujimori and Takehiko Tominaga and Takao Okubo and Akira Ito and Makio Kurihara and Kaitaro Yamabe and Kazufuto Fukaya and Fumio Matsumoto and Shigeki Odagiri and Masanori Matsumura and Kaneo Suzuki and Koou Murohashi and Hisako Suzuki and Yasuhiro Yoshiike and Mitsuyo Kiuchi and Tsutomu Fukuda and Kaoru Oyama and Toshihiko Takeuchi and Masahito Kato and Hidekazu Hanaki and Toshiyuki Yamamoto and Hideki Nishiyama and Takekuni Iwata and Kazukiyo Oida and Yoshiro Mochizuki and Mitsuo Hase and Yujiro Suzuki and Nobuaki Ikeda and Shozo Fujino and Tetsuya Matsumoto and Hiroyuki Tsujino and Kenji Bando and Naoaki Kuroda and Fumiyuki Kuze and Yuruko Okamoto and Seibun Yonezu and Yube Iida and Yoshihiko Sakakibara and KōZiro Yasunaga and Yoshihiro Ueda and Hiroshi Okubo and Fumio Miki and Yoshiyasu Ikuno and Eiji Inoue and Akihito Murata and Tanizawa, {Shin Ichi} and Kazuo Sakamoto and Hirozumi Sakai and Rinzo Soejima and Hiroshi Kawane and Yoshihito Niki and Yoshihisa Nakagawa and Osamu Moriya and Eiro Tsubura and Masakazu Tamura and Toshihiro Gotoh and Masaru Nakagawa and Koichi Fukuyama and Tadaaki Morimoto and I. Teiho and Masami Ito and Naoyoshi Kojiro and Osamu Kurimura and Hideo Sasaki and Hirofumi Fukuhara and Tadao Morimoto and Yoshiro Sawae and Kaoru Okada and Yukio Kumagai and Hitoshi Nagano and Torao Inoue and Chiharu Kubo and Keizo Matsumoto and Harumi Shishido and Tomoyuki Harada and Masaru Nasu and Jun Goto and Yoichiro Goto and Takayoshi Tashiro and Takashi Itoga and Moritaka Suga and Masayuki Ando and Shukuro Araki and Kazumine Kobari and Masao Nakatomi and Yutoku Kinjo and Tatsuo Ohgimi and Katsuyoshi Shimoji and Yuei Irabu",

year = "1986",

doi = "10.11250/chemotherapy1953.34.629",

language = "English",

volume = "34",

pages = "629--653",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

number = "7",

}

TY - JOUR

T1 - Comparative study of bay o 9867 (ciprofloxacin) and bacampicillin on bacterial pneumonia by double blind method

AU - Hara, Kohei

AU - Saito, Atsushi

AU - Yamaguchi, Keizo

AU - Suzuyama, Yoji

AU - Shigeno, Yoshiteru

AU - Kohno, Shigeru

AU - Watanabe, Koichi

AU - Izumikawa, Kin Ichi

AU - Koteda, Tsunetoshi

AU - Okuno, Kazuhiro

AU - Miyazaki, Takashige

AU - Tsutsumi, Tsuneo

AU - Tomizawa, Masumi

AU - Nakayama, Ichiro

AU - Hiraga, Yohmei

AU - Kikuchi, Kohki

AU - Yamamoto, Asako

AU - Takebe, Kazuo

AU - Kumasaka, Yoshihiro

AU - Aoyagi, Kazumi

AU - Tamura, Toyokazu

AU - Sekino, Keiichi

AU - Irie, Tatsuro

AU - Sagara, Morio

AU - Okamoto, Katsuhiro

AU - Tamura, Masao

AU - Konishi, Kazuki

AU - Daibo, Ataru

AU - Kuramitsu, Hiroshi

AU - Gomi, Kazutoshi

AU - Itakura, Kotaro

AU - Sato, Nobuhisa

AU - Tanifuji, Kazuo

AU - Konno, Kiyoshi

AU - Oizumi, Kotaro

AU - Aonuma, Seiichi

AU - Nagai, Kosaku

AU - Hayashi, Izumi

AU - Katsu, Masataka

AU - Okui, Shinji

AU - Fukui, Toshio

AU - Sato, Minoru

AU - Yokosr, Takasht

AU - Toyota, Takeo

AU - Kawai, Mieko

AU - Yamagata, Hajime

AU - Aoyagi, Teruo

AU - Yoshizawa, Shigeo

AU - Katayama, Tetsuji

AU - Higashi, Fuyuhiko

AU - Masuda, Gohta

AU - Negishi, Masayoshi

AU - Young, Chenden

AU - Sekine, Osamu

AU - Usuda, Yoshimaru

AU - Aoki, Nobuki

AU - Yamasaki, Fusanosuke

AU - Suzuki, Yasutoshi

AU - Kobayashi, Hiroyuki

AU - Takamura, Kenji

AU - Takeda, Hiroaki

AU - Kono, Kota

AU - Katoh, Masakazu

AU - Yamane, Yoshiji

AU - Mashimo, Keimei

AU - Kabe, Junzaburo

AU - Ishibashi, Hiroyoshi

AU - Sano, Yasuyuki

AU - Kudo, Koichiro

AU - Uno, Yuko

AU - Ikemoto, Hideo

AU - Watanabe, Kazuyoshi

AU - Tanimoto, Hiroichi

AU - Nakata, Koichiro

AU - Nakamori, Yoshitaka

AU - Chonabayashi, Naohiko

AU - Nakatani, Ryuo

AU - Yoshimura, Kunihiko

AU - Miyahara, Tadashi

AU - Koyama, Masaru

AU - Watanabe, Kentaro

AU - Iijima, Fukuo

AU - Kobayashi, Yoshio

AU - Fujimori, Ippei

AU - Tominaga, Takehiko

AU - Okubo, Takao

AU - Ito, Akira

AU - Kurihara, Makio

AU - Yamabe, Kaitaro

AU - Fukaya, Kazufuto

AU - Matsumoto, Fumio

AU - Odagiri, Shigeki

AU - Matsumura, Masanori

AU - Suzuki, Kaneo

AU - Murohashi, Koou

AU - Suzuki, Hisako

AU - Yoshiike, Yasuhiro

AU - Kiuchi, Mitsuyo

AU - Fukuda, Tsutomu

AU - Oyama, Kaoru

AU - Takeuchi, Toshihiko

AU - Kato, Masahito

AU - Hanaki, Hidekazu

AU - Yamamoto, Toshiyuki

AU - Nishiyama, Hideki

AU - Iwata, Takekuni

AU - Oida, Kazukiyo

AU - Mochizuki, Yoshiro

AU - Hase, Mitsuo

AU - Suzuki, Yujiro

AU - Ikeda, Nobuaki

AU - Fujino, Shozo

AU - Matsumoto, Tetsuya

AU - Tsujino, Hiroyuki

AU - Bando, Kenji

AU - Kuroda, Naoaki

AU - Kuze, Fumiyuki

AU - Okamoto, Yuruko

AU - Yonezu, Seibun

AU - Iida, Yube

AU - Sakakibara, Yoshihiko

AU - Yasunaga, KōZiro

AU - Ueda, Yoshihiro

AU - Okubo, Hiroshi

AU - Miki, Fumio

AU - Ikuno, Yoshiyasu

AU - Inoue, Eiji

AU - Murata, Akihito

AU - Tanizawa, Shin Ichi

AU - Sakamoto, Kazuo

AU - Sakai, Hirozumi

AU - Soejima, Rinzo

AU - Kawane, Hiroshi

AU - Niki, Yoshihito

AU - Nakagawa, Yoshihisa

AU - Moriya, Osamu

AU - Tsubura, Eiro

AU - Tamura, Masakazu

AU - Gotoh, Toshihiro

AU - Nakagawa, Masaru

AU - Fukuyama, Koichi

AU - Morimoto, Tadaaki

AU - Teiho, I.

AU - Ito, Masami

AU - Kojiro, Naoyoshi

AU - Kurimura, Osamu

AU - Sasaki, Hideo

AU - Fukuhara, Hirofumi

AU - Morimoto, Tadao

AU - Sawae, Yoshiro

AU - Okada, Kaoru

AU - Kumagai, Yukio

AU - Nagano, Hitoshi

AU - Inoue, Torao

AU - Kubo, Chiharu

AU - Matsumoto, Keizo

AU - Shishido, Harumi

AU - Harada, Tomoyuki

AU - Nasu, Masaru

AU - Goto, Jun

AU - Goto, Yoichiro

AU - Tashiro, Takayoshi

AU - Itoga, Takashi

AU - Suga, Moritaka

AU - Ando, Masayuki

AU - Araki, Shukuro

AU - Kobari, Kazumine

AU - Nakatomi, Masao

AU - Kinjo, Yutoku

AU - Ohgimi, Tatsuo

AU - Shimoji, Katsuyoshi

AU - Irabu, Yuei

PY - 1986

Y1 - 1986

N2 - The clinical effectiveness and safety of BAY o 9867 (Ciprofloxacin, CPFX) in the treatment of the patients with bacterial pneumonia were compared with those of bacampicillin (BAPC) by a double-dummy fashion. Patients over 18 years old with apparent clinical signs and symptoms of pneumonia were administered with CPFX at a daily dose of 600 mg or BAPC at a daily dose of 1 g orally for 14 days in principle. The following results were obtained. 1) On the basis of committee judgement, the clinical efficacy rate in the total cases including non-bacterial pneumonia was 85.3% (58/68) in CPFX group and 90.5% (57/63) in BAPC group, respectively. In bacterial pneumonia, the rate was 83.3% (45/54) in CPFX group and 88. 9% (40/45) in BAPC group, respectively. The differences between the two groups in both analyses were statistically not significant. 2) The clinical efficacy rate by doctors in charge in the total cases was 87.7% (57/65) in CPFX group and 86.9% (53/61) in BAPC group, respectively. In bacterial pneumonia, the rate was 86.8% (46/53) for CPFX group and 87.2% (41/47) for BAPC group, respectively. In both analyses, the differences between the two groups were statistically not significant. 3) As for the bacteriological response, the eradication rate in the total cases was 85.7% (18/21) in CPFX group and 65. 0% (13/20) in BAPC group, respectively. In bacterial pneumonia, the eradication rate was 83.3% (15/18) in CPFX group and 56.3% (9/16) in BAPC group, respectively. In both analyses, the rates of CPFX were higher than those of BAPC, but statistically, the differences between the two groups were not significant. 4) Side effects were noted in 7 of 83 cases (8. 4%) treated with CPFX and 8 of 84 cases (9. 5%) with BAPC, and abnormal changes in laboratory findings were noted in 12 of 80 cases (15.0%) with CPFX and 18 of 77 cases (23.4%) with BAPC. The differences between the two groups were not significant statistically. Neither serious side effect nor remarkable abnormal change in laboratory findings was noted. 5) The utility rates judged by the committee members and by doctors in charge were not significantly different between the two groups. From these results, it is considered that the clinical efficacy and safety of CPFX at a daily dose of 600 mg are equal to those of BAPC at a daily dose of 1g in the treatment of the patients with bacterial pneumonia.

AB - The clinical effectiveness and safety of BAY o 9867 (Ciprofloxacin, CPFX) in the treatment of the patients with bacterial pneumonia were compared with those of bacampicillin (BAPC) by a double-dummy fashion. Patients over 18 years old with apparent clinical signs and symptoms of pneumonia were administered with CPFX at a daily dose of 600 mg or BAPC at a daily dose of 1 g orally for 14 days in principle. The following results were obtained. 1) On the basis of committee judgement, the clinical efficacy rate in the total cases including non-bacterial pneumonia was 85.3% (58/68) in CPFX group and 90.5% (57/63) in BAPC group, respectively. In bacterial pneumonia, the rate was 83.3% (45/54) in CPFX group and 88. 9% (40/45) in BAPC group, respectively. The differences between the two groups in both analyses were statistically not significant. 2) The clinical efficacy rate by doctors in charge in the total cases was 87.7% (57/65) in CPFX group and 86.9% (53/61) in BAPC group, respectively. In bacterial pneumonia, the rate was 86.8% (46/53) for CPFX group and 87.2% (41/47) for BAPC group, respectively. In both analyses, the differences between the two groups were statistically not significant. 3) As for the bacteriological response, the eradication rate in the total cases was 85.7% (18/21) in CPFX group and 65. 0% (13/20) in BAPC group, respectively. In bacterial pneumonia, the eradication rate was 83.3% (15/18) in CPFX group and 56.3% (9/16) in BAPC group, respectively. In both analyses, the rates of CPFX were higher than those of BAPC, but statistically, the differences between the two groups were not significant. 4) Side effects were noted in 7 of 83 cases (8. 4%) treated with CPFX and 8 of 84 cases (9. 5%) with BAPC, and abnormal changes in laboratory findings were noted in 12 of 80 cases (15.0%) with CPFX and 18 of 77 cases (23.4%) with BAPC. The differences between the two groups were not significant statistically. Neither serious side effect nor remarkable abnormal change in laboratory findings was noted. 5) The utility rates judged by the committee members and by doctors in charge were not significantly different between the two groups. From these results, it is considered that the clinical efficacy and safety of CPFX at a daily dose of 600 mg are equal to those of BAPC at a daily dose of 1g in the treatment of the patients with bacterial pneumonia.

UR - http://www.scopus.com/inward/record.url?scp=0022472114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022472114&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.34.629

DO - 10.11250/chemotherapy1953.34.629

M3 - Article

AN - SCOPUS:0022472114

SN - 0009-3165

VL - 34

SP - 629

EP - 653

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

IS - 7

ER -

Comparative study of bay o 9867 (ciprofloxacin) and bacampicillin on bacterial pneumonia by double blind method

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this